FAQ'S

DOES LifeBridge Innovations, PBC HAVE A WORKING RELATIONSHIP WITH NOVOCURE THE LEADER IN THE FIELD OF TTF?

No. We are totally independent and have no connection to NovoCure.

is LifeBridge Innovations, PBC a competitor of novocure?

No. In our opinion the work of LifeBridge Innovations is complimentary to that of NovoCures. We estimate that, like all Pioneering companies, NovoCure had to prioritize its long path toward making TTF the 4th modality for cancer. From our point of view, it is perfectly logical that they have chosen to seek approval for the treatment of cancers in single areas. For example, Brain Cancer in the Brain Only,  Lung Cancer in the Lung only, Pancreatic Cancer in the pancreas only, etc. However, in our opinion, this path leaves the metastatic patient with disease in multiple locations 7 to 10 years away from a functioning system that can adequately deliver TTF. We believe our work is like we have gone 10 years out into the future and are working back toward NovoCure. In the end, we believe our efforts will serve the mutual goal of the two companies, which is to make TTF available to as many cancer victims as possible, sooner. If by some magic, we could treat all the patients in our target market, in our opinion it would not take any patients away from NovoCure for the foreseeable future.        

Is the LifeBridge Innovations Tumor Treating device available to treat patients today?

No. Further product development is needed and several FDA requirements must be met before treatment can begin. Management estimates that it will take 18 to 24 months from the time we are fully funded to begin treating patients in foreign countries. At present, LifeBridge Innovations, PBC is not fully funded. When first released, the device will not be eligible for reimbursement through health insurance companies.

Is tumor treating fields a cure for cancer?

No. TTF is a treatment. When used 12 to 18 hours a day, it can reduce and eliminate cancer tumors over weeks (tiny tumors) and months/years (larger tumors). If the TTF fields are stopped prematurely, in most cases, the cancer will begin to growing again immediately.

Once cancer tumors are fully eliminated by TTF, will they come back when the treatment is stopped?

Cancer is unpredictable, but in most cases, stage 4 disease returns. We plan to experiment with TTF used as a preventative treatment. However, to date, there have been no completed clinical trials studying TTF as a prevention for recurrence.

Does TTF work long term for patients with stage 4 cancer?

Treating cancer patients long term with TTF requires handling new variables that arise over time. While it is not completely understood, tumor cells of long-term TTF patients tend to change in size. The frequency of TTF is determined by cell size. It may be that the original frequency used on a TTF patient effectively kills nearly all of a dominate range of cell sizes. Tumor cell sizes outside the range of the original frequency then begin to emerge. Another observation is that the cells can take on volume (become larger) while under the influence of a TTF. If the original frequency chosen does not cover a wide enough range of cell sizes, some cell escapage can occur. It may be required that long-term TTF patients obtain biopsies that can determine accurate cells size so that frequencies can be adjusted. Long-term cancer patients with compromised immune systems may also not benefit from TTF. Immune system health must be maintained in TTF patients.